sintilimab
Unswayed by a discount pledge, FDA adcomm rejects Lilly’s PD-1 drug
Phil Taylor
Eli Lilly, fda, immuno-oncology, Non-small cell lung cancer, Oncology, sintilimab
0 Comment
X
Unswayed by a discount pledge, FDA adcomm rejects Lilly’s PD-1 drug
https://pharmaphorum.com/news/unswayed-by-lillys-discount-pledge-fda-adcomm-rejects-its-pd-1-drug/
FDA won’t back Lilly’s PD-1 antibody based on Chinese data alone
Phil Taylor
Eli Lilly, fda, Innovent, Non-small cell lung cancer, sintilimab
0 Comment
X
FDA won’t back Lilly’s PD-1 antibody based on Chinese data alone
https://pharmaphorum.com/news/fda-wont-review-lillys-pd-1-antibody-based-on-chinese-data-alone/
Good news for Lilly as sintilimab hits the spot in lung cancer again
Phil Taylor
Eli Lilly, immuno-oncology, Innovent, lung cancer, Oncology, sintilimab
0 Comment
X
Good news for Lilly as sintilimab hits the spot in lung cancer again
https://pharmaphorum.com/news/good-news-for-lilly-as-sintilimab-hits-the-spot-in-lung-cancer-again/
FDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy option
Richard Staines
cancer, Eli Lilly, Innovent, lung cancer, sintilimab
0 Comment
X
FDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy option
https://pharmaphorum.com/news/fda-review-of-lilly-innovents-sintilimab-paves-way-for-cut-price-immunotherapy-option/